SRI has developed a promising new treatment for this cancer of the immune system that affects plasma cells in bone marrow.
SRI is identifying candidates for advanced therapies in multiple disease areas by developing compounds from synthetically optimized, natural dietary products.
SRI is developing a new therapeutic agent for influenza virus infections.
SRI researchers are searching for new molecular targets that allow for discovery of more selective anticancer agents.
Using synthetic lethality to ID biomarkers for targeted anti-cancer drugs.